Status:
COMPLETED
Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx
Lead Sponsor:
DR. MALA KHAN
Collaborating Sponsors:
Bangladesh Reference Institute of Chemical Measurements (BRICM)
Conditions:
Virus Infection, RNA
Effect of Drug
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The COVID-19 pandemic is the defining global health crisis of our time and the greatest challenge we have faced since World War-II.Corona virus is transmitted via respiratory droplets or aerosol, prod...
Detailed Description
Introduction: COVID-19 pandemic is the defining global health crisis of our time and the greatest challenge we have faced since World War Two. We have now reached the tragic milestone of two million ...
Eligibility Criteria
Inclusion
- A. Moderately ill COVID-19 patient and asymptomatic to mild COVID-19 patent having multiple comorbidity
- Inclusion Criteria
- Hospital admitted patients tested positive COVID-19 within 24 hours in the laboratory by RT-PCR.
- Patients with asymptomatic, mild to moderate illness of COVID-19.
- Age group 18 year and above.
- Consent of the patients, wish to be included in the study willingly.
Exclusion
- Patients with critical COVID-19 and moderate COVID-19 with other complication.
- Patients having thyroid dysfunction, pregnant or lactating mother.
- It should not be used prior to or after radioiodine scintigraphy or radioiodine treatment of thyroid carcinoma.
- Patients allergic to iodine should be avoided
- Have participated in other clinical study
- Subjects with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial.
- B. Healthy Individual
- Inclusion Criteria:
- Healthy individual (non COVID-19)
- Age -18 years and above (as below18 years lesser concentration of drug may be required).
- Consent of the participants who wish to participate.
- Exclusion criteria:
- Participants who has any major comorbidity.
- Participants having thyroid dysfunction, pregnant or lactating mother.
- It should not be used prior to or after radioiodine scintigraphy or radioiodine treatment of thyroid carcinoma.
- Participants allergic to iodine should be avoided
- Have participated in other clinical study
- Subjects with other severe acute or chronic conditions that may increase the risk of participation in the study and study treatment, or may interfere with interpretation of study results, and judged by the investigator as not suitable for participation in this clinical trial.
Key Trial Info
Start Date :
April 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 30 2021
Estimated Enrollment :
798 Patients enrolled
Trial Details
Trial ID
NCT04872686
Start Date
April 10 2021
End Date
May 30 2021
Last Update
January 20 2022
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Bangladesh Reference Institute for Chemical Measurements
Dhaka, Dhanmondi, Bangladesh, 1205
2
Dhaka Medical College Hospital
Dhaka, Bangladesh, 1000
3
Kurmitola General Hospital
Dhaka, Bangladesh, 1206
4
Kuwait-Moitree Hospital
Dhaka, Bangladesh, 1230